Multimodal Treatment of Gastric Cancer: Surgery, Chemotherapy, Radiotherapy, and Timing
1General Oncologic Surgery, Careggi University Hospital, Florence, Italy
Multimodal Treatment of Gastric Cancer: Surgery, Chemotherapy, Radiotherapy, and Timing
Description
In the scenario of gastric cancer treatment surgery is no more alone since many years. Although the encouraging results of adjuvant chemotherapy with S-1 obtained in Japan were not achieved in Western countries, a novel approach, after the results of MAGIC trial published in 2006, has been introduced with pre- or perioperative chemotherapy in the West, with many trials ongoing.
Radiotherapy has been used for many years now in USA with good results and is part of many schedules in Europe as well. Chemotherapy has been proposed even in an intraperitoneal setting with hyperthermia, after extensive resection and peritonectomy.
Multimodal treatment is therefore mandatory, to date, for gastric cancer, but timing, type of therapies, and schedules seem to be a puzzle yet.
We invite investigators to submit original articles and reviews of the literature to shed light on this topic.
Our prominent interests are on results in terms of overall survival with different multimodal schedules as well as complete response to preoperative treatments. Moreover impact of multimodal treatments on surgical perioperative complications and side effects should be taken into account. Particularly significant are those studies which investigate factors and methods capable of predicting multimodal treatments response for different patients in order to tailor a specific treatment to each case. Translational research, molecular genetics, and molecular diagnostics are of utmost interest for such a prospective. Potential topics include, but are not limited to:
- Recent results in multimodal treatment of gastric cancer
- Different schedule of multimodal treatment, their feasibility, and their results
- Patients selection, inclusion, and exclusion criteria for multimodal treatments
- Prediction of response and diagnostic tools
- Advance in translational research and molecular genetics and diagnostics
- Advance in predictors and prognostic factors identification
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijso/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: